Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
22 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Biohaven Ltd.’s names, not what it holds today.
Patents granted
22
22 utility, 1976 to Dec 31, 2025
Granted in 2025
12
Against 5 in 2024 and 3 in 2023
Applications published
13
1 of them in 2025
Names they are printed under
5
a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
Organic fine chemistry8
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
BIOHAVEN THERAPEUTICS LTD. a subsidiary
VG, as the owner printed on each patent. 14 more under the same name are not counted (printed in US, printed in JP)
0 publishedKLEO PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
7 publishedPYRAMID BIOSCIENCES, INC. a subsidiary
named as the applicant on its applications, in US
6 publishedPyramid Biosciences, Inc. a subsidiary
US, as the owner printed on each patent
0 publishedKLEO PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
0 publishedNames not counted (1)
Biohaven Therapeutics Ltd.
Most of its patents print US; this name counts in VG. 0 granted and 55 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 2, 2025 | 12,486,276 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | Organic fine chemistry | Pyramid Biosciences, Inc. |
| Nov 18, 2025 | 12,472,165 | Riluzole prodrugs and their use | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| Aug 12, 2025 | 12,383,619 | Use of glutamate modulating agents with immunotherapies to treat cancer | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| Jul 29, 2025 | 12,370,176 | Methods of use for KV7 channel activators | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| Jul 22, 2025 | 12,364,687 | Use of riluzole oral disintegrating tablets for treating diseases | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| Jul 8, 2025 | 12,351,559 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | Organic fine chemistry | BIOHAVEN THERAPEUTICS LTD. |
| Jul 1, 2025 | 12,343,347 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| May 13, 2025 | 12,297,206 | Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt | Pharmaceuticals | BIOHAVEN THERAPEUTICS LTD. |
| May 13, 2025 | 12,295,942 | Riluzole prodrugs and their use | Biotechnology | BIOHAVEN THERAPEUTICS LTD. |
| Apr 29, 2025 | 12,286,408 | KV7 channel activators compositions and methods of use | Organic fine chemistry | BIOHAVEN THERAPEUTICS LTD. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 31, 2025 | 2025/0243216 | CD16A BINDING AGENTS AND USES THEREOF | Organic fine chemistry | KLEO PHARMACEUTICALS, INC. |
| Jul 25, 2024 | 2024/0246976 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | Organic fine chemistry | PYRAMID BIOSCIENCES, INC. · patent 12,486,276 granted from it |
| Mar 21, 2024 | 2024/0092778 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | Pharmaceuticals | PYRAMID BIOSCIENCES, INC. |
| Feb 15, 2024 | 2024/0051966 | CD16A BINDING AGENTS AND USES THEREOF | Organic fine chemistry | KLEO PHARMACEUTICALS, INC. · patent 12,162,892 granted from it |
| Aug 3, 2023 | 2023/0242536 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | Organic fine chemistry | PYRAMID BIOSCIENCES, INC. |
| Apr 27, 2023 | 2023/0128688 | DIRECTED CONJUGATION TECHNOLOGIES | Pharmaceuticals | KLEO PHARMACEUTICALS, INC. |
| Apr 20, 2023 | 2023/0124248 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | Organic fine chemistry | PYRAMID BIOSCIENCES, INC. · patent 11,739,096 granted from it |
| Nov 10, 2022 | 2022/0356191 | CD16A BINDING AGENTS AND USES THEREOF | Organic fine chemistry | KLEO PHARMACEUTICALS, INC. · patent 11,572,370 granted from it |
| Jul 28, 2022 | 2022/0235055 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | Organic fine chemistry | PYRAMID BIOSCIENCES, INC. |
| Feb 10, 2022 | 2022/0040231 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | Pharmaceuticals | KLEO PHARMACEUTICALS, INC. · patent 12,491,246 granted from it |
What it applied for, 2024 to 2025: Organic fine chemistry 3 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.